Detalles de la búsqueda
1.
Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.
Blood
; 142(3): 235-243, 2023 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37140031
2.
Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials.
Oncologist
; 29(4): 356-363, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676048
3.
Impact of an evolving regulatory landscape on skin cancer drug development in the U.S.
Dermatol Online J
; 28(2)2022 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35670678
4.
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Oncologist
; 26(4): 318-324, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33345396
5.
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
Oncologist
; 26(9): 797-806, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973307
6.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196068
7.
The On- and Off-Ramps of Oncology Accelerated Approval.
N Engl J Med
; 387(16): 1439-1442, 2022 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36129992
8.
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Oncologist
; 24(1): 103-109, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30120163
9.
Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests.
JAMA Oncol
; 10(3): 380-383, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175622
10.
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
Clin Cancer Res
; 30(2): 269-273, 2024 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676259
11.
Challenges and Solutions to Support Oncology Professionals Serving Underserved Populations With Cancer in the United States: Results From the ASCO Serving the Underserved Task Force.
JCO Oncol Pract
; 20(5): 688-698, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38354324
12.
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer.
Clin Cancer Res
; 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38856639
13.
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Clin Cancer Res
; 2024 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38809262
14.
Remote Monitoring and Data Collection for Decentralized Clinical Trials.
JAMA Netw Open
; 7(4): e246228, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38607626
15.
Equitable Access to Clinical Trials: How Do We Achieve It?
Am Soc Clin Oncol Educ Book
; 43: e389838, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37146264
16.
Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients.
PLoS One
; 18(2): e0281182, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36812168
17.
Assessing the Needs of Those Who Serve the Underserved: A Qualitative Study among US Oncology Clinicians.
Cancers (Basel)
; 15(13)2023 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37444421
18.
Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges.
Clin Cancer Res
; 29(18): 3566-3572, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37378578
19.
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
Clin Cancer Res
; 29(11): 2020-2024, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36485007
20.
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity.
Clin Lymphoma Myeloma Leuk
; 23(6): 463-470.e1, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37076368